Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis - Takeaways - MDSpire

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis

  • By

  • Hao Su

  • Xinyu Zhao

  • Huayu Liu

  • Mianli Li

  • Haitao Geng

  • July 1, 2026

  • 0 min

Share

  • 1

    Immune checkpoint inhibitors, like Sintilimab, can induce type 1 diabetes mellitus (ICI-T1DM) with irreversible damage to pancreatic β cells.

  • 2

    A 69-year-old female patient developed ICI-T1DM after receiving Sintilimab and the SOX regimen for poorly differentiated adenocarcinoma.

  • 3

    The patient exhibited severe hyperglycemia and elevated serum β-hydroxybutyrate, indicating acute pancreatic injury linked to PD-1 inhibitor therapy.

  • 4

    ICI-T1DM typically presents with negative autoantibodies, distinguishing it from classic autoimmune type 1 diabetes.

  • 5

    Blood glucose levels stabilized with insulin therapy, but the patient later experienced diabetic ketoacidosis during treatment.

Original Source(s)

Type 1 diabetes mellitus induced by sintilimab: a case report and related case literature analysis

  • by Hao Su, Xinyu Zhao, Huayu Liu, Mianli Li, Haitao Geng

  • July 1, 2026

Related Content

From voice biomarkers to telemedicine screening: developing and evaluating a voice-based AI model for laryngeal lesion detection using the Bridge2AI-Voice dataset

Comparison between germline and somatic loss-of-function RNF43 mutations reveals different genotype-phenotype associations and provides insights into the genetic mechanisms of colorectal tumourigenesis

CTSG-expressing mast cells confer resistance to immunotherapy in colorectal cancer